Association of muscular fitness with rehospitalization for heart failure with reduced ejection fraction

Chan Joo Lee MD, PhD | Ho Youl Ryu PT, PhD | Kyeong-Hyeon Chun MD | Jaewon Oh MD, PhD | Sungha Park MD, PhD | Sang-Hak Lee MD, PhD | Seok-Min Kang MD, PhD

Abstract

Background: Limited information is available regarding the prognostic potential of muscular fitness parameters in heart failure (HF) with reduced ejection fraction (HFrEF).

Hypothesis: We aimed to investigate the predictive potential of knee extensor muscle strength and power on rehospitalization and evaluate the correlation between exercise capacity and muscular fitness in patients newly diagnosed with HFrEF.

Methods: Ninety-nine patients hospitalized with a new diagnosis of HF were recruited (64 men; aged 58.7 years [standard deviation (SD), 13.2 years]; 32.3% ischemic; ejection fraction, 28% [SD, 8%]). The inclusion criteria were left ventricular ejection fraction <40% and sufficient clinical stability to undergo exercise testing. Aerobic exercise capacity was measured with cardiopulmonary exercise testing. Knee extensor maximal voluntary isometric contraction (MVIC) and muscle power (MP) were measured using the Baltimore therapeutic equipment system. The clinical outcome was HF rehospitalization.

Results: Over a mean follow-up period of 1709 ± 502 days, 39 patients were rehospitalized due to HF exacerbation. HF rehospitalization was more probable for patients with diabetes and lower oxygen uptake at peak exercise (peak VO₂), knee extensor MVIC, and MP. The Kaplan–Meier survival analysis revealed significantly different cumulative HF rehospitalization rates according to the tertiles of peak VO₂ (P = 0.005) and MP (P = 0.002). Multivariable Cox proportional hazard model showed that the lowest tertiles of peak VO₂ (hazard ratio (HR), 6.26; 95% confidence interval (CI), 1.93–20.27); and MP (HR, 5.29; 95% CI, 1.05–26.53) were associated with HF rehospitalization. Knee extensor muscle power was an independent predictor for rehospitalization in patients with HFrEF.

Conclusion: Knee extensor muscle power was an independent predictor for rehospitalization in patients with HFrEF.

KEYWORDS
heart failure, muscle power, muscle strength, rehospitalization

All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
1 | INTRODUCTION

Heart failure (HF) is a chronic debilitating disease associated with a 50% mortality rate within 5 years of diagnosis. Despite advancements in treatment strategies, HF still poses a significant threat to patient outcomes. Patients with HF often complain of fatigue and shortness of breath even with low-intensity physical activity, which causes detrimental effects to their quality of life. Exercise intolerance is a consequence of HF and a major determinant of its prognosis. Measurement of peak oxygen uptake (peak VO₂) during exercise is an objective method for assessing functional capacity and is an important predictor of long-term prognosis in patients with HF. Peak VO₂ is used for determining the timing of heart transplantation. The loss of muscle mass and strength occurs progressively with aging. Irrespective of aging, chronic diseases accelerate the atrophy of muscle fibers or lower the efficiency of energy production in the muscles, leading to low levels of muscular fitness, which is also associated with poor prognosis. In patients with HF, muscular strength predict long-term survival. However, the effect of muscle fitness on rehospitalization has not been fully investigated. Muscular strength is one of the most common indicators of muscular fitness. However, muscle performance can also be measured as muscle power (MP), which indicates the ability of the muscle to perform forceful and high-velocity movements. Furthermore, as the measurement of MP is technically simple and relatively easy to assess, it could be incorporated into a standard prognostic assessment for patients with HFrEF. Nevertheless, indices of muscular fitness are rarely used in real-world clinical practice, unlike peak VO₂.

Therefore, we aimed to do the following: (a) investigate the predictive potential of knee extensor muscle strength and power on rehospitalization; and (b) evaluate the correlation between exercise capacity and muscular fitness in patients newly diagnosed with HFrEF.

2 | MATERIAL AND METHODS

2.1 | Study participants

We recruited consecutively a total of 99 patients, who were hospitalized with a new diagnosis of HF from January 2013 to November 2015, received subsequent inpatient treatment, and were discharged. The inclusion criteria were as follows: left ventricular ejection fraction <40% and sufficient clinical stability to undergo exercise testing. Patients who underwent surgical procedures such as coronary artery bypass, valve replacement, heart transplantation, and those on renal replacement therapy were excluded. Aerobic exercise capacity and muscular fitness were examined immediately before discharge. We investigated the medications prescribed at discharge and obtained blood chemistry data at the time of the 1–2 week follow-up visit. Definition of heart failure rehospitalization was a hospitalization caused by worsening heart failure symptoms and signs requiring the augmentation of previous medications. We identified cases of heart failure rehospitalization by chart reviewing. All patients provided written informed consent at enrollment, and the Ethics Committee of Severance Hospital of the Yonsei University Health System approved the protocol (No. 4-2018-1180). The study was performed in accordance with the Declaration of Helsinki.

2.2 | Assessment of aerobic exercise capacity

Functional exercise capacity was evaluated during the maximal treadmill exercise test using the Bruce RAMP protocol with the cardiopulmonary exercise test (CPET) system CASE T2100 (GE Healthcare, Chicago, IL) under the supervision of a cardiologist. Respiratory gas exchange analysis was performed throughout the exercise protocol with a Quark gas analysis system (COSMED, Rome, Italy).

2.3 | Assessment of muscular fitness

The assessments of two muscular fitness parameters were performed using the Primus RS, version 11 (Baltimore Therapeutic Equipment Technology, Hanover, MD). For knee extensor muscle strength, the maximal voluntary isometric contraction (MVIC) and MP were measured. For measurements of MVIC (Supplemental Video File 1), participants were instructed to push with maximum force while keeping the knee flexed at 45°, and the mean value of three measurements was obtained. To compensate for differences in body weight among participants, the value was divided into MVIC per kg of body weight for use in the statistical analysis. For the assessment of MP (Supplemental Video File 2), resistance corresponding to 20% of body weight was applied to compensate for differences in body weight between the participants, after which, participants were instructed to flex and extend the knees with maximum effort. The mean value of the top five results from 10 measurements was used in the statistical analysis.

2.4 | Statistical analysis

Data were expressed as mean ± standard deviation (SD) frequency (%), or median (interquartile range [IQR]). Patients were grouped based on whether they required HF rehospitalization. For group comparison of continuous variables, the Student’s t-test, one-way analysis of variance, the Mann–Whitney U test, or the Kruskal-Wallis test was used. Categorical variables were evaluated using chi-squared test or Fisher’s exact test. Correlation analysis between aerobic exercise capacity and muscular fitness was performed using Pearson’s correlation coefficient. The effect of aerobic exercise capacity or muscular fitness on HF rehospitalization was analyzed using Kaplan–Meier curves. Receiver operating characteristic (ROC) analysis was performed to identify the best cut-off value of peak VO₂, MVIC, and MP for HF rehospitalization.
rehospitalization. The association of the tertile of aerobic exercise capacity or muscular fitness with HF rehospitalization was evaluated using a multivariable Cox proportional hazard model with adjustment for age, sex, body mass index, diabetes mellitus, and left ventricular ejection fraction (LVEF), and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Statistical analyses were conducted using R software, version 3.5.3 (R Foundation for Statistical Computing, Vienna, Austria), assuming a threshold of significance at $P < 0.05$.

3 | RESULTS

3.1 | Baseline characteristics of patients

Table 1 shows the baseline characteristics of the patients. The mean age was 58.7 years (SD, 13.2 years), and 64 patients (66.3%) were male. Their left ventricular (LV) systolic function was markedly impaired (mean LVEF, 27.5% [SD, 8.1%]). Ischemic cardiomyopathy accounted for 32.3% of the etiologies of HF.

During the follow-up period (mean: 1691 days [SD, 512 days]; median: 1762 days [IQR, 1588–2059 days]), 39 patients (39.4%) were rehospitalized due to HF aggravation. Patients with rehospitalization had lower LVEF and a higher rate of diabetes than those without HF rehospitalization. Regarding HF guideline-directed medications at baseline, the use of beta-blockers was significantly lower in patients with HF rehospitalization than in those without HF rehospitalization. The use of other medications was not significantly different between the two groups.

Table 2 shows the results of CPET and muscular fitness tests. Patients with rehospitalization had significantly lower heart rates at rest and maximal exercise in CPET. The systolic blood pressure did not differ between the two groups at rest; however, it was lower during maximal exercise in patients with rehospitalization. Moreover, the exercise time and peak VO$_2$ were significantly lower in patients with

| TABLE 1 | Baseline characteristics according to rehospitalization in total subjects |
|----------|-----------------|-----------------|-----------------|---------|
| Demographic findings | Total (N = 99) | No rehospitalization (N = 60) | Rehospitalization (N = 39) | P value |
| Age, years | 58.3 ± 13.3 | 57.3 ± 12.2 | 59.9 ± 15.0 | 0.351 |
| Men, N(%) | 64 (64.6%) | 43 (71.7%) | 21 (53.8%) | 0.110 |
| Height, cm | 163.9 ± 8.9 | 164.6 ± 9.0 | 162.7 ± 8.6 | 0.276 |
| Weight, kg | 64.4 ± 14.7 | 65.7 ± 13.0 | 62.4 ± 16.9 | 0.274 |
| BMI, kg/m$^2$ | 23.8 ± 4.1 | 24.1 ± 3.6 | 23.4 ± 4.8 | 0.427 |
| LV ejection fraction, % | 27.5 ± 8.1 | 29.1 ± 8.4 | 25.1 ± 7.3 | 0.018 |
| Sinus rhythm, N(%) | 73 (73.7%) | 44 (73.3%) | 29 (74.4%) | 0.999 |
| DM, N(%) | 25 (27.8%) | 9 (17.3%) | 16 (42.1%) | 0.018 |
| Hypertension, N(%) | 39 (43.3%) | 21 (40.4%) | 18 (47.4%) | 0.656 |
| Ischemic cardiomyopathy, N(%) | 32 (32.3%) | 22 (36.7%) | 10 (25.6%) | 0.354 |
| Laboratory findings | | | | |
| BUN, mg/dl | 18.5 ± 6.6 | 18.4 ± 5.9 | 18.8 ± 7.7 | 0.769 |
| Creatinine, mg/dl | 0.9 ± 0.4 | 1.0 ± 0.2 | 0.9 ± 0.5 | 0.390 |
| Serum total protein, d/dl | 6.7 ± 0.6 | 6.8 ± 0.7 | 6.7 ± 0.6 | 0.662 |
| Serum albumin, d/dl | 4.0 ± 0.5 | 4.0 ± 0.5 | 3.9 ± 0.4 | 0.559 |
| Na$, mmol/L | 140.0 ± 2.6 | 140.4 ± 2.4 | 139.4 ± 2.9 | 0.071 |
| K$, mmol/L | 4.4 ± 0.5 | 4.5 ± 0.5 | 4.3 ± 0.4 | 0.078 |
| NT-proBNP, pg/ml | 1389.5 (718.0–2248.0) | 1429.5 (680.0–2263.0) | 1342.5 (817.0–1943.5) | 0.840 |
| Medications at discharge | | | | |
| ACE inhibitor, N(%) | 42 (42.4%) | 24 (40.0%) | 18 (46.2%) | 0.691 |
| ARB, N(%) | 36 (36.4%) | 23 (38.3%) | 13 (33.3%) | 0.771 |
| Beta blocker, N(%) | 75 (75.8%) | 52 (86.7%) | 23 (59.0%) | 0.004 |
| Ivabradine, N(%) | 10 (10.1%) | 5 (8.3%) | 5 (12.8%) | 0.702 |
| Loop diuretics, N(%) | 74 (74.7%) | 43 (71.7%) | 31 (79.5%) | 0.523 |
| MRA, N(%) | 74 (74.7%) | 45 (75.0%) | 29 (74.4%) | 0.999 |

Note: Data are presented as mean ± SD, N(%) or median (IQR).
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; DM, diabetes mellitus; LV, left ventricular; CMP; MRA, mineralocorticoid antagonist; NT-proBNP, N-terminal pro B-type natriuretic peptide; SD, standard deviation.
rehospitalization, indicating a clear difference in aerobic exercise performance between the two groups. The MVIC was significantly lower in patients with rehospitalization. The MP also tended to be lower in patients with HF rehospitalization. These results showed that the patients with HF rehospitalization presented with lower values for skeletal muscle fitness parameters than those without rehospitalization.

3.2 | Correlations among parameters of exercise capacity and muscular fitness

Patients with higher muscular fitness exhibited higher aerobic exercise capacity (Supplemental Figure 1). MVIC ($r = 0.52$; 95% confidence interval (CI), 0.36–0.65; $P < 0.001$) and MP ($r = 0.50$; 95% CI, 0.34–0.63; $P < 0.001$) showed good correlation with peak VO₂ (Figure 1(A), (B)). In addition, MVIC and MP showed high correlation ($r = 0.84$; 95% CI, 0.78–0.89; $P < 0.001$; Figure 1(C)).

3.3 | Muscular fitness as a predictor for rehospitalization

Supplemental Table 1 shows the incidence of HF rehospitalization during the follow-up period according to the peak VO₂, MVIC, and MP tertiles. The incidence of HF rehospitalization was significantly different according to the peak VO₂ tertile. Patients were divided into three groups (low, middle, and high) according to the tertiles of peak VO₂, MVIC, and MP. Patients with lower aerobic exercise capacity had more HF rehospitalizations during follow-up (Figure 2). Patients with lower MVIC tended to present with HF rehospitalization more frequently; however, the difference was not statistically significant (Supplemental Table 1), as was the case with the Kaplan–Meier survival curve (Figure 2). Nevertheless, patients with low MP had significantly more HF rehospitalizations than the other groups (Supplemental Table 1). The Kaplan–Meier curve showed that patients with low MP were rehospitalized for HF at early periods of follow-up (Figure 2). ROC curves showed that the best cut-off values of peak VO₂, MVIC, and MP for HF rehospitalization was 20.1 ml/kg, 320 N, and 87 Watt, respectively (Supplemental Figure 2). The best cut-off value of peak VO₂ was similar to the high tertile value, while the best cut-off values of MVIC and MP were similar to the low tertile values.

In the multivariable Cox proportional hazard model (Table 3), low LVEF and DM were important predictors for HF rehospitalization. Patients with low peak VO₂ had a significantly higher risk of HF rehospitalization than those with high peak VO₂ (hazard ratio, 6.26; 95% CI, 1.93–20.27; $P = 0.002$). Of the indicators for muscular fitness, only MP showed a significant association with HF rehospitalization. The patients in the low MP group were 5.29-times more apt to be rehospitalized for HF than those in the high MP group.

### Table 2 | Parameters of cardiopulmonary exercise test and muscle fitness measurement according to rehospitalization in total subjects

|                        | Total (N = 99) | No rehospitalization (N = 60) | Rehospitalization (N = 39) | P value |
|------------------------|---------------|-------------------------------|---------------------------|---------|
| **Cardiopulmonary exercise test** |               |                               |                           |         |
| Heart rate at rest, bpm | 84.3 ± 17.6   | 87.4 ± 18.3                   | 79.5 ± 15.3               | 0.028   |
| SBP at rest, mmHg      | 106.8 ± 17.9  | 108.7 ± 19.6                  | 103.8 ± 14.8              | 0.187   |
| Peak VO₂, ml/kg/min    | 20.0 ± 5.6    | 21.6 ± 5.6                    | 17.7 ± 4.6                | <0.001  |
| Exercise time, sec     | 546.3 ± 196.7 | 604.2 ± 184.8                 | 457.2 ± 182.6             | <0.001  |
| AT, ml/kg/min          | 15.7 ± 5.7    | 16.4 ± 5.8                    | 14.7 ± 5.6                | 0.161   |
| RER at peak            | 1.1 ± 0.1     | 1.1 ± 0.1                     | 1.1 ± 0.1                 | 0.273   |
| VE/VCO₂ slope          | 36.8 ± 8.2    | 35.7 ± 7.9                    | 38.4 ± 8.5                | 0.115   |
| PetCO₂, mmHg           | 33.5 ± 6.7    | 33.7 ± 5.5                    | 33.2 ± 8.4                | 0.746   |
| HR at maximal exercise, bpm | 137.5 ± 28.3 | 145.1 ± 30.7                  | 125.9 ± 19.5              | <0.001  |
| HR reserve, bpm        | 53.3 ± 22.8   | 57.8 ± 24.9                   | 46.4 ± 17.3               | 0.009   |
| SBP at maximal exercise, mmHg | 150.1 ± 30.7 | 157.4 ± 31.3                  | 139.0 ± 26.3              | 0.003   |
| SBP reserve, mmHg      | 43.4 ± 23.6   | 48.7 ± 24.8                   | 35.2 ± 19.3               | 0.005   |
| HRR/SBPR               | 1.6 ± 1.6     | 1.6 ± 1.8                     | 1.7 ± 1.1                 | 0.651   |

| **Muscle fitness measurement** |               |                               |                           |         |
| MVIC (N)                 | 373.3 ± 138.6 | 399.6 ± 131.4                 | 332.9 ± 141.2             | 0.018   |
| MP (Watt)                | 134.1 ± 74.3 | 145.7 ± 67.5                  | 116.2 ± 81.3              | 0.052   |

Abbreviations: AT, anaerobic threshold; HR, heart rate; HRR, heart rate reserve; MP, muscle power; MVIC, maximum voluntary isometric contraction; PetCO₂, pulmonary end-tidal CO₂; RER, respiratory exercise ratio; SBP, systolic blood pressure; SBPR, systolic blood pressure reserve; VCO₂, carbon dioxide production; VE, ventilatory equivalents; VO₂, oxygen uptake.
In this study, we found that both MP and MVIC were lower in patients with HF rehospitalization than in those without rehospitalization. Both these parameters also exhibited a significant correlation with the peak VO2. However, low MP (and not MVIC) was significantly associated with the risk of rehospitalization for HF in patients with HFrEF.

HF rehospitalization incurs high medical costs, putting a great burden on patients, the health care system, and the social economy. In addition, it may contribute to the long-term progression of HF and LV dysfunction.14 In this study, DM and LVEF are the most significant factors for predicting HF rehospitalization. It is known that HF patients with DM have a higher risk of HF rehospitalization and a worse prognosis than those without DM.15 Also, low LVEF is closely associated with cardiovascular outcomes in HF patients.16 Despite adjustment of important prognostic factors such as diabetes and LVEF, our study showed that low aerobic exercise capacity and low muscular fitness are significant prognostic factors related to HF rehospitalization.

Peak VO2 is the most objective indicator of physical fitness that represents the use of oxygen in the cardiac, circulatory, and respiratory systems and muscles.17 CPET is recommended in the 2016 European HF Guidelines for identifying the cause of unexplained dyspnea or for determining the treatment policies.2 CPET can provide a more global assessment of patients with HF. CPET parameters are valid prognostic factors for HF, especially peak VO2 is closely related to the long-term prognosis of HF.7 In our analysis, among the CPET parameters, peak VO2 was most closely associated with to HF rehospitalization (Supplemental Table 2). Our study showed that muscular fitness is also a major predictor of HF prognosis. The isokinetic strength test of the knee flexor muscle showed that the strength index was significantly associated with mortality, although peak VO2 was adjusted in multivariable analysis for patients with advanced HF.6 Despite the clear association between muscular fitness and long-term outcomes of HF, muscular fitness is used less frequently than peak VO2 for assessing the patients’ condition in the clinical settings.

Consistent poor exercise tolerance was observed in the patients with HF and hypothesized to be due to the pathophysiological changes in the skeletal muscle.18 Histologic studies on the skeletal
muscles in HF identified reduced capillary density and decreased mitochondrial volume.\textsuperscript{19,20} Excessive activation of the sympathetic nervous system and upregulation of the cytokine system induced a decrease in proteins in the muscle and destruction of those proteins, thereby reducing muscle mass.\textsuperscript{21} These muscle-wasting conditions correlated with maximum peak oxygen uptake in patients with HF.\textsuperscript{22} In our study, muscular fitness and peak VO\textsubscript{2} were significantly correlated, and patients with low MP, probably those with low peak VO\textsubscript{2}, had poor prognosis for HF. These findings suggested that the association of MP with the prognosis of HF is comparable to that of peak VO\textsubscript{2}. In addition, muscular fitness variables in combination with peak VO\textsubscript{2} can more reliably predict hospitalization for heart failure. The prognostic ability of the combination of peak VO\textsubscript{2} and muscular fitness variable was analyzed using the best cut-off values obtained using ROC analysis. When the peak VO\textsubscript{2} was low and the MP or MVIC was low, the risk of re-hospitalization due to HF was 9–20 times higher than that of the high peak VO\textsubscript{2} and high MP or MVIC (data not shown). However, since the number of subjects is small, further research is needed.

As it is generally recommended to measure peak VO\textsubscript{2} rather than muscular fitness in evaluating the physical fitness of patients with HF, exercise training is primarily focused on aerobic endurance exercise.\textsuperscript{2} Resistance training is a form of exercise that contracts the muscles against opposing forces that create resistance, overloading the musculoskeletal system to prevent muscle loss and improve the muscle strength.\textsuperscript{23} Although resistance training has survival benefits in patients with HF, increased afterload during the lifting phase in resistance training may adversely affect the LV function and cause negative remodeling.\textsuperscript{24} Therefore, exercise training aimed at improving muscular fitness in patients with HF has not been widely used. Nevertheless, a position statement of the European Journal of Heart Failure recommends a patient-specific strength-training program relying on the accurate and meticulous evaluation of each patient's physical fitness.\textsuperscript{24} This suggests that there is a need for a reliable method for evaluating muscular fitness that can be safely practiced in patients. However, in several studies, methods for measuring muscular fitness are inconsistent, resulting in a lack of consensus regarding objective representative indicators of muscular fitness. As patients with chronic diseases such as HF have lesser muscular fitness than healthy individuals, it may be difficult to apply general methods of measuring muscular fitness to these patients.

Muscular strength is the force that a muscle or muscle group exerts against resistance in maximal effort. MVIC is a standardized, objective, and sensitive tool for measuring muscle strength.\textsuperscript{25} Power is defined as the product of force and distance divided by the change in time. As a measure of muscular fitness, it can be challenging to separate muscle strength and MP because measuring muscle strength and power is a dynamic process. In our study, the two indicators were closely related. However, when comparing the values of the two indicators as functional measures of muscle performance, MP appeared to be slightly better. In adults aged \textgreater_65 years, decreased MP affects physical performance three times more than decreased muscle strength.\textsuperscript{26} MP decreases with age, possibly occurring earlier than changes in peak muscle strength; this has drawn attention as an essential predictor of reduced activity in older patients.\textsuperscript{27}

Only a few studies have measured MP and strength separately in patients with HF; to the best of our knowledge, this is the first study to analyze the long-term prognostic relationship of these two indicators with HF. We demonstrated that MP was a better indicator of muscular fitness for predicting the long-term prognosis of HF than MVIC, an indicator of muscle strength. The measurement of MVIC may cause the Valsalva maneuver, which may induce stress in the left ventricle.\textsuperscript{24} As the MP measurement method used in our study is performed according to the individual weight load, it is possible to measure muscular fitness more safely. Therefore, measuring MP as an indicator of prognosis in patients with HF and for guiding muscle training to reduce muscle loss may be useful for facilitating a multidisciplinary approach towards HF.

This study has several limitations. First, our subjects were those who had physical activity sufficient to measure both CPET and

### TABLE 3 Multivariable Cox proportional hazard regression analyses for HF rehospitalization according to the tertiles of aerobic exercise capacity and muscle fitness

|                | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value |
|----------------|------------|---------|------------|---------|------------|---------|
| Age            | 1.00 (0.97–1.02) | 0.733 | Age        | 0.99 (0.97–1.02) | 0.692 | Age        | 0.99 (0.95–1.03) | 0.540 |
| Female         | 1.18 (0.54–2.55) | 0.681 | Female     | 1.31 (0.54–3.22) | 0.551 | Female     | 0.97 (0.36–2.60) | 0.945 |
| BMI            | 1.01 (0.91–1.11) | 0.897 | BMI        | 1.01 (0.90–1.13) | 0.869 | BMI        | 1.04 (0.84–1.15) | 0.431 |
| DM             | 2.96 (1.50–5.85) | 0.002 | DM         | 3.54 (1.69–7.42) | <0.001 | DM         | 2.64 (1.34–5.21) | 0.005 |
| LVEF           | 0.93 (0.88–0.97) | 0.001 | LVEF       | 0.92 (0.88–0.97) | <0.001 | LVEF       | 0.93 (0.69–0.97) | 0.002 |
| NT-proBNP      | 1.00 (1.00–1.00) | 0.837 | NT-proBNP  | 1.00 (1.00–1.00) | 0.831 | NT-proBNP  | 1.00 (1.00–1.00) | 0.804 |
| Peak VO\textsubscript{2} tertile | MVIC tertile | MP tertile |
| High           | Reference | -       | High       | Reference | -       | High | Reference | - |
| Middle         | 2.85 (0.98–8.31) | 0.054 | Middle     | 1.19 (0.40–3.52) | 0.752 | Middle     | 1.32 (0.37–4.77) | 0.668 |
| Low            | 6.26 (1.93–20.27) | 0.002 | Low        | 3.11 (0.80–12.20) | 0.102 | Low        | 5.29 (1.05–26.53) | 0.043 |

Abbreviations: BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection fraction; MP, muscle power; MVIC, maximum voluntary isometric contraction; NT-proBNP, N-terminal pro b-type natriuretic peptide; VO\textsubscript{2}, oxygen uptake.
muscular fitness. Therefore, there was a high possibility that patients with severe muscle loss were not included, and it might be difficult to generalize the results of this study to all patients with severe advanced HF. Nevertheless, measuring MP will not be difficult in patients with disability because its feasibility has been demonstrated in older populations with sarcopenia. Second, we did not demonstrate that MP was related to the prognosis of HF independently of peak VO$_2$. This is because peak VO$_2$ and MP were highly correlated and subjects with low peak VO$_2$ or low muscular fitness shared clinical features such as old age, female, and high NT-proBNP levels (Supplemental Table 3–7). However, the fact that MP was significantly associated with the prognosis of HF as much as peak VO$_2$ suggests that measuring MP in patients is an alternative to measuring physical fitness. Third, the medications used after discharge were not reflected in the research results. In addition, lower prescription of beta-blockers at discharge in patients with low MP may have had an impact on long-term prognosis. Fourth, the number of subjects who participated in the study was relatively small.

In conclusion, aerobic exercise capacity and muscle fitness were associated with the prognosis of patients with HFrEF. Compared with MVIC, which is the traditional method of measuring knee extensor fitness, measurement of MP was found to be a better predictor for HF rehospitalization in these patients.

ACKNOWLEDGMENTS
We would like to thank Editage (www.editage.co.kr) for English language editing.

CONFLICT OF INTEREST
The authors declare that they have no competing interests.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Chan Joo Lee https://orcid.org/0000-0002-8756-409X
Sang-Hak Lee https://orcid.org/0000-0002-4535-3745
Seok-Min Kang https://orcid.org/0000-0001-9856-9227

REFERENCES
1. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397-1402.
2. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200.
3. Pina IL, Apstein CS, Balady GJ, et al. Exercise and heart failure: a statement from the American Heart Association Committee on exercise, rehabilitation. And Prevention Circulation. 2003;107:1210-1225.
4. Taylor RS, Walker S, Smart NA, et al. Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis. J Am Coll Cardiol. 2019;73:1430-1443.
5. Myers J, Gullestad L, Vagelos R, et al. Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure. Am Intem Med. 1998;129:286-293.
6. Hulsmann M, Quitman M, Berger R, et al. Muscle strength as a predictor of long-term survival in severe congestive heart failure. Eur J Heart Fail. 2004;6:101-107.
7. Malhotra R, Bakken K, D’Ella E, et al. Cardiopulmonary exercise testing in heart failure. JACC Heart Fail. 2016;4:607-616.
8. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778-786.
9. Goldspink G. Age-related loss of muscle mass and strength. J Aging Res. 2012;2012:158279.
10. Ebner N, Slizik V, Scherbakov N, Sandek A. Muscle wasting in ageing and chronic illness. ESC Heart Fail. 2015;2:58-68.
11. Artero EG, Lee DC, Lavié CJ, et al. Effects of muscular strength on cardiovascular risk factors and prognosis. J Cardiopulm Rehabil Prev. 2012;32:351-358.
12. Jackson SL, Tong X, King RJ, Loustalot F, Hong Y, Ritchey MD. National burden of heart failure events in the united states, 2006 to 2014. Circ Heart Fail. 2018;11(12):e004873. http://dx.doi.org/10.1161/circheartfailure.117.004873.
13. Zannad F, Garcia AA, Anker SD, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15:1082-1094.
14. Gheorghiade M, De Luca L, Fonarow GC, et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96:11g-17g.
15. Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34:1404-1413.
16. Solomon SD, Anavekars N, Skall H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112:3738-3744.
17. Guazzi M, Adams V, Conraads V, et al. EACPR/AHA scientific statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2012;126:2261-2274.
18. Stewart Coats AJ. From the muscle hypothesis to a muscle solution? ESC Heart Fail. 2019;6:229-240.
19. Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation. 1990;81:518-527.
20. Massie BM, Noyes P, Yancy R, et al. 31P nuclear magnetic resonance evidence of abnormal skeletal muscle metabolism in patients with congestive heart failure. Am J Cardiol. 1987;60:309-315.
21. Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999;20:683-693.
22. Fulster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating comorbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013;34:512-519.
23. Williams MA, Haskell WL, Ades PA, et al. Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American Heart Association Committee on clinical cardiology and council on nutrition, physical activity, and metabolism. Circulation. 2007;116:572-584.
24. Piepoli MF, Conraads V, Corra U, et al. Exercise training in heart failure: from theory to practice. A consensus document of the heart failure association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail. 2011;13:347-357.
25. Meldrum D, Cahalane E, Keoghan F, Hardiman O. Maximum voluntary isometric contraction: investigation of reliability and
learning effect. *Amyotroph Lateral Scler Other Motor Neuron Disord*. 2003;4:36-44.

26. Bean JF, Leveille SG, Kiely DK, et al. A comparison of leg power and leg strength within the InCHIANTI study: which influences mobility more? *J Gerontol A Biol Sci Med Sci*. 2003;58:728-733.

27. Reid KF, Pasha E, Doros G, et al. Longitudinal decline of lower extremity muscle power in healthy and mobility-limited older adults: influence of muscle mass, strength, composition, neuromuscular activation and single fiber contractile properties. *Eur J Appl Physiol*. 2014;114(1):29-39. http://dx.doi.org/10.1007/s00421-013-2728-2.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Lee CJ, Ryu HY, Chun K-H, et al. Association of muscular fitness with rehospitalization for heart failure with reduced ejection fraction. *Clin Cardiol*. 2021;44:244–251. [https://doi.org/10.1002/clc.23535](https://doi.org/10.1002/clc.23535)